Empresaria (EMR.L) Empressive finish to the year



Similar documents
Year-end Dec 2013A 2014E 2015E 2016E Key data. # Priced at market close, 29/09/14

Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3

DATRON AG. Investor day supports our positive view. Buy (Buy) EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015

QUADRANT SKEW CAPITAL Syllabus

Expert System. Strong organic growth with acquisition upside. Growth in annual licensing key to shareholder return

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

BDI BioEnergy Internat Buy

Direct Equities - Best Ideas for Retiree Portfolios

Graphite Electrodes. Imposition of antidumping duty augurs well. Sector Update. ICICI Securities Ltd Retail Equity Research.

HCC BUY. Infrastructure January 29, 2016

CEWE Stiftung & Co. KGaA

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors

Kingdee (268 HK) Buy (maintained) Target price: HK$3.58. Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$3.

potential of business still not fully exploited; PT raised to Q results vs. estimates IFRS Q3 15 Q2 15 qoq Q3 14 yoy Q3 15e delta

Results Presentation for Year Ended 30 June August 2015

SUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH

INVESTMENT CASE FULLY INTACT

Maruti Suzuki. Source: Company Data; PL Research

for Analysing Listed Private Equity Companies

Khambatta Securities Ltd.

Background information. Changes in the shareholder structure and balance sheet. Contract with Google prolonged for two years

Simplex Infrastructures

SOHO CHINA (410.HK) At the Key Phase of Business Transformation. Neutral (Update) HONG KONG PROPERTY COMPANY UPDATE.

Accumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH

MATELAN Research. Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES

Analyst & Investor Presentation Interim results to 30 June 2011

Petroceltic. FY12 Preview Transitioning to a new level Equity Research 18 Apr Oil & Gas. Inaugural results statement as a merged entity

euromicron AG Corrections to financial statements Hold EUR

22 December 2015 YOC AG. FIRST BERLIN Equity Research

Fundamental analysis. Course 10

BDI BioEnergy Intern Neutral. Activity level in Q3 might not support FY estimates

Exhibit 1: Financial summary of First Tractor in 1H12-1H14 1H12 2H12 1H13 2H13 1H14 (% YoY)

20 May 2015 OpenLimit Holding AG. FIRST BERLIN Equity Research

BUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value

Strong operational performance

PI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI

Software AG Results 1 st Quarter 2015 (IFRS, unaudited)

Klöckner & Co SE. Q Results

HEG Ltd (HEG) 160. Performs well. Result Update. ICICI Securities Ltd Retail Equity Research. November 10, 2015

FLETCHER BUILDING INVESTOR STRATEGY DAY

Financial Repression: A Driving Force for Mergers and Acquisitions?

VODAFONE AGREES TO ACQUIRE CONTROL OF HUTCH ESSAR IN INDIA

BUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP Target Price SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010

Investor and analyst factsheet

Tupras OUTPERFORM (M) 15 February Strong 2009 results on refining side...

For the year ended: 31 Mar 31 Mar (million ) Change Net sales % Gross profit %

2 September 2015 YOC AG. FIRST BERLIN Equity Research

Presentation to Analysts 2009 Preliminary Results. 16 March 2010

Increasing estimates and PT on expectation of solid earnings momentum. Growth momentum and turnaround of insurance business

Results Presentation. Half-Year Ended 31 December ASX Code: SAI. Tony Scotton Chief Executive Officer. 15 February 2011

Vaughan Bowen, MD/CEO

Private Equity investment in Recruitment companies - what are we looking for? Chris Harper Managing Director Baird Capital

No Signs of Cannibalization

The Ramco Cements. Source: Company Data; PL Research

OIM plc. Speculative buy (unchanged) Research-Update March 14 th, 2012 Opportunity Investment Management plc.

Sagicor Life Jamaica Limited Gail Ansine Mgr. Research & Fin. Analysis gansine@scotiadbg.com

Flexituff International Ltd. (FIL)

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

A.B.N A.C.N.

ZetaDisplay. Europe leads the way. EPaccess

ANALYST PRESENTATION 9M 2011 November 9, 2011

The Credit Analysis Process: From In-Depth Company Research to Selecting the Right Instrument

Ludwigshafen, February 25, 2014

COMPUTERSHARE LIMITED (ASX:CPU) FINANCIAL RESULTS FOR THE FULL YEAR ENDED 30 JUNE August 2014

Tree House Education & Accessories

OptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures

SOHO China (410) Buy Nov 20, Company update. 4 Acquisitions within 6 Months. Samson Man, CFA (852) samson.man@firstshanghai.com.

PRIMA INDUSTRIE. Further margin improvement. Buy (maintained) Company Update

Deutsche Bank Global Transaction Banking. What DR investors are buying: An analysis of investment drivers for depositary receipts

Third quarter results as of December 31, Investor presentation

IFGL REFRACTORIES LTD. RESULT UPDATE PRESENTATION, February 2016

HCL Technologies BUY. Performance Highlights CMP. `857 Target Price `1,132. 1QFY2016 Result Update IT. 3-year price chart

SK Networks ( KS)

Q1 Trading Update, FY 2011

FIRST CAPITAL. Sound 2014 results and attractive dividend. Buy (maintained) Company Update

BUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights

Mphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research

The Scottish Investment Trust PLC

Share Capital Increase

Atrium Mortgage Investment Corporation (TSX: AI) Record Year / Shares at Attractive Entry Levels. Sector/Industry: Mortgage Investment Corporation

Valuation approaches to Mergers & Acquisitions

IPO Analysis: China Pacific Insurance (2601): The second largest

Q1 RESULTS APRIL Harald Wilhelm I Chief Financial Officer

Full-year results December 02, 2014

HOLD. Q4 earnings beat but order backlog flat ABB. Target Price: Rs 1,213. Key drivers

Biostime International (1112 HK) Expensive acquisition brings more challenges; maintain SELL

GlaxoSmithKline Consumer Healthcare

SUB: STANDARD CHARTERED PLC (THE "COMPANY") STOCK EXCHANGE ANNOUNCEMENT

HOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights

Company Overview. Financial Performance

Transcription:

26 th January 2015 56 54 52 50 48 46 EMR EMPRESARIA ORD 5P Empresaria (EMR.L) Empressive finish to the year 44 42 40 38 Q1-2014 Q2-2014 Q3-2014 Q4-2014 Price: 43.0p Sourc e: Fides s a 12m High 56.0p 12 m Low 39.5p Mkt cap 19.7m Shares 45.8m (diluted) Sector Market Broker Website Support Services London (AiM) Shore Cap www.empresaria.com Description: Multi-brand international recruitment agency, with 20 brands in 20 countries, with focus on specialist segments of the market. Last week s pre-close trading statement from Empresaria shows that the hard work it did through the recession is now paying off well. Full year profitability will be slightly ahead of consensus and we are upgrading for a second time in a month. We are upgrading FY14E EPS (Dil. Adj.) by 9% to 7.1p and FY15E by 9% to 7.7p. The share price has done little in the last 12 months and continues to be valued at a material discount to its peers. We would expect the discount to narrow assuming Empresaria continues to deliver as (or better than) expected. Underlying improvements coming through: Empresaria now expects PBT (Adj.) to be c13% up on FY13 and we have pushed our FY14 forecast ahead to 6.1m from 5.9m and our FY15 forecast to 7.1m from 7.0m. Net Fee income was 3% ahead of the prior year, despite on-going adverse currency pressures. We calculate that the conversion ratio rose by an impressive 90bps to 15.0%, the third year of progress towards its long-term goal of 20%. In Germany there was a significant hike in profitability following the painful restructuring of operations in 2012 and 2013. India also traded well during the year. Empresaria does not mention current trading but industry evidence elsewhere suggests that the H2 momentum should have continued into the new year. Building for the future: Empresaria has not inflated performance by cutting back on investment. FY14 it opened new offices in Hong Kong, Malaysia, Chile and Mexico and acquired a 75% stake in Ball and Hoolahan in December for an initial cash payment of 1.0m. Despite this activity, total debt (now including non-recourse finance) fell to 9.8m at end 2014 from 15.2m in 2013 and leaves Empresaria well placed to invest further should the right opportunities present themselves. Attractive valuation: The three large, mid-cap UK quoted staffers (Hays, Page and SThree) are trading on forwad PERs of 20.5x (CY14E, unweighted average). The small cap staffers (Harvey Nash, Hydrogen, Matchtech, Robert Walters and Staffline) are trading on 14.3x (FY14E, unweighted average). Empresaria is trading on a prospective PER of 6.1x. Nigel Parson +44 (0)20 7148 0541 np@hardmanandco.comave made been Dec Year End FY11 FY12 FY13 FY14E FY15E Sales ( m) 208.9 194.3 194.4 195.9 197.9 Net Fee Income ( m) 46.9 43.9 42.6 43.9 47.3 Operating profit ( m) 5.3 5.4 6.0 6.6 7.5 PBT ( m) 4.4 4.6 5.4 6.1 7.1 EPS (p) 4.7 5.0 6.2 7.1 7.7 DPS (p) 0.4 0.4 0.4 0.4 0.4 Net (debt)/cash ( m) (15.7) (14.5) (15.2) (9.8) (9.3) Net debt/ebitda (x) 2.6 2.3 2.2 1.3 1.1 P/E (x) 9.2 8.6 7.0 6.1 5.6 EV/Sales (x) 0.2 0.2 0.2 0.2 0.1 EV/NFI (x) 0.8 0.8 0.8 0.7 0.6 FCF Yield (%) 2.5 11.2 23.9 32.1 23.7 Dividend Yield (%) 0.8 0.8 0.8 0.8 0.8

FY11 FY12 FY13 FY14E FY15E 26 th January 15 Key data Net fee income (by type, FY13) Net fee income (by geography, FY13) Net fee income ( m), NFI growth (%) EBIT ( m), NFI conversion (%) Net debt/cash ( m) Capital Employed ( m), RoIC (RHS, %) 18 16 14 12 10 8 6 4 2 0 3.0 2.5 2.0 1.5 1.0 0.5 - Net debt ( m) Net debt:ebitda (x, RHS) 2

Valuation charts EV/Net Fee Income (12 month prospective, x) The shares are slowly starting to appreciate in value as the recovery story gains traction. PER (12 month prospective, %) We would expect the investment proposition and anticipated earnings growth to be increasingly reflected in an expansion of rating from its current level of 6.1x FY14E PER. EV/EBITDA (pros 12 months) Likewise, we would expect the investment case to be reflected in the expansion of its EV/EBITDA multiple. 3

Key financials Dec Year End FY11 FY12 FY13 FY14E FY15E P&L ( m) Sales 208.9 194.3 194.4 195.9 197.9 Net Fee Income ( m) 46.9 43.9 42.6 43.9 47.3 EBITDA 6.1 6.3 6.9 7.5 8.4 Operating profit 5.3 5.4 6.0 6.6 7.5 PBT 4.4 4.6 5.4 6.1 7.1 EPS 4.7 5.0 6.2 7.1 7.7 DPS 0.4 0.4 0.4 0.4 0.4 Cashflow ( m) Operating cash flow 3.9 5.2 7.8 9.2 8.2 Interest & tax (2.7) (2.5) (2.3) (2.1) (2.9) Capex / Acquisitions (1.0) (3.5) (1.9) (2.4) (1.1) Dividends (0.2) (0.2) (0.2) (0.2) (0.2) Equity - - - - - Other items (1.1) 2.2 (4.1) 0.8 (3.5) Change in net debt (1.1) 1.2 (0.7) 5.4 0.5 Closing net debt (15.7) (14.5) (15.2) (9.8) (9.3) Balance sheet ( m) Net assets 28.2 24.0 24.7 27.3 30.7 Key metrics FY11 FY12 FY13 FY14E FY15E Growth (%) Sales 1.0 (6.4) (3.0) 3.0 7.8 Net Fee Income 0.9 (6.4) (3.0) 3.0 7.8 Operating profit (28.4) 1.9 11.1 10.0 14.3 EPS (24.6) 7.1 23.0 15.5 8.9 DPS 0 0 0 0 0 Operating ratios (%) Gross margins 22.5 22.6 21.9 22.4 23.9 EBITDA margins 13.0 14.4 16.2 17.1 17.9 Operating margins 11.3 12.3 14.1 15.0 16.0 Effective tax rate 39.0 39.0 39.0 33.0 35.0 Leverage Gearing (%) 55.7 60.4 61.5 35.9 30.2 Net debt/ebitda (x) 2.6 2.3 2.2 1.3 1.1 Interest cover (x) 4.3 5.8 11.1 18.4 20.4 EPS/DPS (x) 13.4 14.3 17.6 20.3 22.1 4

Disclaimer Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Hardman & Co provides professional independent research services and the company covered in this note pays us a set fee in order for this research to be made available. The conclusions and opinions expressed in this report reflect the views of the analysts named on the front page. Whilst every reasonable effort has been made to ensure that the information in the research is correct, this cannot be guaranteed. The report is intended to be clear, fair and not misleading. Hardman & Co has a personal dealing policy which debars staff and consultants from dealing in shares, bonds or other related instruments of companies which pay Hardman for any services, including research. They may be allowed to hold such securities if they were owned prior to joining Hardman or if they were held before the company appointed Hardman. In such cases sales will only be allowed in limited circumstances, generally in the two weeks following publication of figures. Hardman & Co does not buy or sell shares, either for its own account or for other parties and neither does it undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly we do not publish records of our past recommendations. Where a Fair Value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities/companies but has no scheduled commitment and may cease to follow these securities/companies without notice. This research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated or retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Past performance of a security is not necessarily a guide to the future and the price of shares and bonds, and the income derived from them, may fall as well as rise and the amount realised may be less than the original sum invested. Shares quoted on the Alternative Investment Market (AIM) are subject to a lighter regulatory regime than those on the main market and may, thus, be subject to more risk. Furthermore AIM shares may not be as marketable as those on the main market. In some cases research is only issued electronically, whilst in other cases printed research will be received by those on our distribution lists later than those subscribing to research electronically. This report may not be reproduced in whole or in part without prior permission from Hardman &Co. Follow us on Twitter @HardmanandCo Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS United Kingdom Tel: +44(0)20 7929 3399 Fax: +44(0)20 7929 3377 www.hardmanandco.com 5